Check out Comprehensive Prescribing Data OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed following autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or just after 3 or even more traces of systemic therapy that inclu